Cookie Policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read ourPrivacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

News

 

 

Terumo Launches QuiremSpheres® Microspheres in Europehttp://www.terumo-europe.com/en-emea/news/terumo-launches-quiremspheres®-microspheres-in-europeTerumo Launches QuiremSpheres® Microspheres in EuropeTokyo, Japan18/09/2017 22:00:00<p><font size="3">Terumo Corporation (TSE: 4543)announced today thatit has launched QuiremSpheres® microspheres on September 18 in Europe. QuiremSpheres®are available in Europe with plans for expansion in areas outside of Europe in the future.</font></p><font size="3"></font>
Terumo Announces European Medicines Agency Validates Marketing Authorization Application for a Biosimilar to Be Formulatedhttp://www.terumo-europe.com/en-emea/news/terumo-announces-european-medicines-agency-validates-marketing-authorization-application-for-a-biosimilar-to-be-formulatedTerumo Announces European Medicines Agency Validates Marketing Authorization Application for a Biosimilar to Be FormulatedTokyo, Japan22/05/2017 22:00:00<p>​<span>To Accelerate Global Expansion of PLAJEX™</span></p>
First patient enrolled in major new study investigating abbreviated DAPT post-stent in high bleeding risk patientshttp://www.terumo-europe.com/en-emea/news/first-patient-enrolled-in-major-new-study-investigating-abbreviated-dapt-post-stent-in-high-bleeding-risk-patientsFirst patient enrolled in major new study investigating abbreviated DAPT post-stent in high bleeding risk patientsEmmen, The Netherlands03/04/2017 22:00:00<h4>​MASTER-DAPT kicks-off with the enrolment of its first patient by Treant Zorggroep, Scheper Hospital </h4>
Terumo announces first commercial clinical case using QuiremSpheres®http://www.terumo-europe.com/en-emea/news/terumo-announces-first-commercial-clinical-case-using-quiremspheres®Terumo announces first commercial clinical case using QuiremSpheres®Leuven, Belgium27/03/2017 22:00:00<h4>​Terumo Europe nv today announced the first commercial clinical case using QuiremSpheres® - the next generation radio-embolization microspheres for advanced unresectable liver cancer.</h4>
Terumo and Toxikon Europe NV announce a strategic partnershiphttp://www.terumo-europe.com/en-emea/news/terumo-and-toxikon-europe-nv-announce-a-strategic-partnershipTerumo and Toxikon Europe NV announce a strategic partnershipLeuven, Belgium05/03/2017 23:00:00